Randomly selected profiles of test set subjects having low (< 2^nd percentile), median (49^th to 51^st percentiles) and high (> 98^th percentile) functional risk scores.

Randomly selected profiles of test set subjects having low (nd percentile), median (49th to 51st percentiles) and high (> 98th percentile) functional risk scores.</p

Cox model results of time to CVD event among test set subjects.

Cox model results of time to CVD event among test set subjects.</p

Subject characteristics in train and test set.

Subject characteristics in train and test set.</p

Simulated coefficient profiles under an alternative hypothesis for nested spline series with 8 and 15 degrees of freedom.

N = 500 (Panel A) and N = 5000 (Panel B). Thick (black) line is true profile. Thin (colored) lines are representative simulated profiles.</p

Example profile.

Solid line represents particle mass for a representative sample lipoprotein profile. Sizes: (VS = very small; S = small; M = Medium; L = Large). Regions: HDL = High Density Lipoprotein; MZ = Midzone; LDL = Low Density Lipoprotein; IDL = Intermediate Density Lipoprotein; VLDL = Very Low Density Lipoprotein.</p

Simulated coefficient profiles under an alternative hypothesis for nested spline series with 7 and 13 degrees of freedom.

N = 500 (Panel A) and N = 5000 (Panel B). Thick (black) line is true profile. Thin (colored) lines are representative simulated profiles.</p

Estimated Cox regression coefficients across ion mobility profile.

Solid line represents estimated regression coefficients. Dashed lines represent upper and lower 95% confidence intervals for regression coefficients. Points indicate regions of significance (95% CI does not include zero). Sizes: (VS = very small; S = small; M = Medium; L = Large) Regions: HDL = High Density Lipoprotein; MZ = Midzone; LDL = Low Density Lipoprotein; IDL = Intermediate Density Lipoprotein; VLDL = Very Low Density Lipoprotein.</p

Simulation results.

Simulation results.</p

Additional file 1: Table S1. of Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis

Health outcomes and costs for different statin treatment strategies for primary prevention of cardiovascular disease in 100,000 hypothetical intermediate risk patients: Base-case analysis. Table S2. Deterministic Sensitivity Analysis. Incremental Cost and Incremental QALY per 100,000 patients for all parameters for the Test and HST strategy 1 compared with the MST strategy. Table S3. Deterministic Sensitivity Analysis. Incremental Cost and Incremental QALY per 100,000 patients for all parameters for the Test and MST strategy 1 compared with the Do-Not-Treat strategy. Table S4. Deterministic Sensitivity Analysis Incremental Cost and Incremental QALY per 100,000 patients for all parameters for the HST strategy compared 1 with the MST strategy. (DOCX 67 kb

Whiskers denote 95% confidence intervals derived from linear mixed models adjusted for age, sex, and principal components of genetic variation.

<p>Whiskers denote 95% confidence intervals derived from linear mixed models adjusted for age, sex, and principal components of genetic variation.</p